Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Mar 2014 · 1 min read
In brief
In brief
This study identifies SMARCA4 gene mutations as a key driver in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), finding germline or somatic inactivating mutations in 75% of cases and protein loss in 82% of tumors. The findings establish SMARCA4 as a critical oncogenic mechanism in this rare, aggressive pediatric and young adult ovarian cancer.
Written by the GCMD Library team from the article.
Statements in this article
Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is an extremely rare, aggressive cancer affecting children and young women.
Germline and somatic inactivating mutations in the SWI/SNF chromatin-remodeling gene SMARCA4 were identified in 75% (9/12) of SCCOHT cases.
SMARCA4 protein loss was found in 82% (14/17) of SCCOHT tumors.
SMARCA4 protein loss was found in only 0.4% (2/485) of other primary ovarian tumors.
SMARCA4 is implicated in SCCOHT oncogenesis.